Execution

Executing contractual documents

Lawyers work on a huge variety of transactions, but all of them will in some way involve written agreements that will need to be executed by the parties. For this reason, it is very important that lawyers know when a deed is required and fully understand the differences in how deeds and simple contracts are executed.

This subtopic summarises the law, guidance and practice relating to simple contracts and deeds, including in particular:

  1. the key elements that must be present to create a contract

  2. what simple contracts are and how they are executed

  3. what a deed is and the particular transactions for which a deed (rather than a simple contract) is required

  4. the formalities for creating valid deeds

  5. guidance on executing deeds and simple contracts in counterpart

  6. how to circulate pre-signed counterpart signature pages and virtual closings

This subtopic contains execution content based on the law of England and Wales. For execution content for Scottish practitioners, see: Execution—Scotland—overview.

The Practice Note: Executing documents—deeds and simple contracts summarises the law and practice relating to simple contracts and deeds, as

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Powered by Lexis+®
Latest Life Sciences News

Life Sciences weekly highlights—3 April 2025

This week's edition of Life Sciences weekly highlights includes analysis by Herbert Smith Freehills LLP of the UK Court of Appeal judgment confirming it cannot deviate from previous UK precedent on second medical use SPCs (Merck Serono v Comptroller-General of Patents), analysis by Arnold & Porter of the Court of Justice decision clarifying whether various promotional schemes offered by pharmacists such as discounts or rewards schemes constitute ‘advertising of medicines’ under Directive 2001/83/EC, as well as, Law360 analyses of the Court of Appeal’s injunction decision striking a compromise to permit rival Glenmark to ship supplies of its generic already packed in trucks without progressing to retail sales (AstraZeneca v Glenmark Pharmaceuticals), the impact of the Unified Patent Court asserting its authority to hear claims involving UK patents, reporting of a nonbinding opinion advising the Court of Justice to uphold a €60.5m fine against Teva and Cephalon for an alleged pay-for-delay conspiracy and the impact of the new EU Product Liability Directive on tech and AI. Also included, is news of the ICO levying a £3.07m fine against Advanced Computer Software Group following a 2022 ransomware attack that compromised personal data including NHS patient data, the European Commission publishing an Explanatory Guide to the microplastics restriction regulation, of MHRA CEO Dame June Raine’s retirement, and the DHSC dispute resolution panel ruling that B. Braun is liable for scheme rebate payments because its off-contract sales of a branded sedative do not qualify for exceptional central procurement exemption under VPAS due to NHS England procurement, among several other important stories.

View Life Sciences by content type :

Popular documents